von Redaktion LCGC | Dez 9, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk...
von Redaktion LCGC | Dez 2, 2014
ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy Rosell R, Karachaliou N, Wolf J, Ou SH Journal: Lancet Respir Med. 2014 Dec;2(12):966-8. doi: 10.1016/S2213-2600(14)70259-0Veröffentlichung: 2. Dezember 2014 (Epub: 19....
von Redaktion LCGC | Dez 1, 2014
Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer: Metastatic Non-small Cell Lung Cancer Ramalingam SS, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H,...
von Redaktion LCGC | Nov 26, 2014
PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies. Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk...
von Redaktion LCGC | Sep 20, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer Lovly CM, McDonald NT, Chen H, Ortiz-Cuaran S, Heukamp LC, Yan Y, Florin A, Ozretić L, Lim D, Wang L, Chen Z, Chen X, Lu P, Paik PK, Shen R, Jin H, Buettner R, Ansén S, Perner S, Brockmann M,...
